Aromatase and prostaglandin inter-relationships in breast adipose tissue: Significance for breast cancer development

Breast Cancer Research and Treatment

Volumn 76, Issue 2, 2002, Pages 103-109

  Karuppu, Darshini ^a   Kalus, Alan ^b   Simpson, Evan R ^a   Clyne, Colin ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b Plastic and Aesthetic Surgery Centre   (Australia)

Author keywords

Aromatase; Breast cancer; Breast mesenchymal cells; Prostaglandin E2; TNF

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; AROMATASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ESTRADIOL; PROSTAGLANDIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; ESTROGEN SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPOSE TISSUE; ADULT; AROMATASE; BREAST; BREAST NEOPLASMS; CELLS, CULTURED; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MIDDLE AGED; STROMAL CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036829273     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020531329686     Document Type: Article

References (33)

1. Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: A cohort study of the elderly. Br Med J 299: 1247-1250, 1989
2. Thun MJ, Namboodiri MM, Heath Jr CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991
3. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Canc Inst 88: 988-993, 1996
4. Friedman GD, Ury HK: Initial screening for carcinogenicity of commonly used drugs. J Natl Canc Inst 65: 723-733, 1980
5. Harris RE. Namboodiri KK, Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7: 203-205, 1996
6. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146, 1994
7. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83: 112-120, 2000
8. Tan WC, Privett OS, Goldyne ME: Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. Canc Res 34: 3229-3231, 1974
9. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T: Prostaglandins and breast cancer. Lancet 2: 624-626, 1977
10. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Canc Inst 64: 1061-1070, 1980
11. 2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Canc 72: 1412-1419, 1995
12. Liu XH, Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Canc Res 56: 5125-5127, 1996
13. Gilhooly EM, Rose DP: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 15: 267-270, 1999
14. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM: Cyclooxygenase-2 expression in human breast cancer. Int J Oncol 10: 503-507, 1997
15. Hwang D, Scollard D, Byme J, Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Canc Inst 90: 455-460, 1998
16. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ: Increased expression of cyclooxygenase-2 in HER-2-overexpressing human breast cancer cells. NCI 7th SPORE Investigator's Workshop
17. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AMC: Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Canc Res 59: 1572-1577, 1999
18. Noguchi M, Taniya T, Koyasaki N, Kumaki T, Miyazaki I, Mizukami Y: Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Canc Res 51: 2683-2689, 1991
19. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Canc Res 60: 2101-2103, 2000
20. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 gene. Endocrinology 137: 5739-5742, 1996
21. O'Neill JS, Elton RA, Miller WR: Aromatase activity in adipose tissue from breast quadrants: A link with tumor site. Br Med J 296: 741-743, 1988
22. Bulun SE, Price TM, Mahendroo MS, Aitken J, Simpson ER: A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77: 1622-1628, 1993
23. Purohit A, Singh A, Ghilchik MW, Reed MJ: Inhibition of tumor necrosis factor α-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochem Biophys Res Commun 261: 214-217, 1999
24. Agarwal VR, Bulun SE, Leitch M, Rohrich R. Simpson ER: Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81: 3843-3849, 1996
25. Harada N, Utsume T, Takagi Y: Tissue-specific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons I and promoters, and switching of tissue-specific exons I in carcinogenesis. Proc Natl Acad Sci USA 90:11312-11316, 1993
26. Zhou D, Zhou C, Chen S: Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells. J Steroid Biochem Mol Biol 61: 273-280, 1997
27. Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier R: Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): An extension of the dietary fat hypothesis of breast cancer. Med Hypotheses 52:291-292, 1999
28. Brueggemeier RW, Quinn AL, Parret ML, Joarder FS, Harris RE, Robertson FM: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140: 27-35, 1999
29. Rubin GL, Zhao Y, Kalus AM, Simpson ER: Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy. Canc Res 60: 1604-1608, 2000
30. Zhao Y, Nichols JE, Bulun SE, Mendelson CR, Simpson ER: Aromatase P450 gene expression in human adipose tissue: Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. J Biol Chem 270: 16449-16457, 1995
31. Zhao Y, Nichols JE, Valdez R, Mendelson CR, Simpson ER: Tumor necrosis factor-α stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol 10: 1350-1357, 1996
32. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR: Aromatase expression in health and disease. Rec Prog Horm Res 52: 185-214, 1997
33. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER: Aromatization of androstenedione by human adipose stromal cells in monolayer culture. J Clin Endocrinol Metab 53: 412-417, 1981